scholarly journals IS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) VAL66MET POLYMORPHISM ASSOCIATED WITH OBSESSIVE-COMPULSIVE DISORDER? A META-ANALYSIS

2019 ◽  
Vol 31 (2) ◽  
pp. 141-147 ◽  
Author(s):  
Shengdong Wang ◽  
◽  
Shengdong Wang ◽  
Xiaohong Xu ◽  
Pan Yan ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Obsessive Compulsive ◽  
Val66met Polymorphism ◽  
Compulsive Disorder ◽  
Bdnf Val66met Polymorphism

Meta-analysis of the association of brain-derived neurotrophic factor Val66Met polymorphism with obsessive–compulsive disorder

2015 ◽  
Vol 27 (6) ◽  
pp. 327-335 ◽  
Author(s):  
Jun Wang ◽  
Fuquan Zhang ◽  
Wenxian Zhu ◽  
Yansong Liu ◽  
Zhenhe Zhou
Keyword(s):  
Psychiatric Disorders ◽  
Obsessive Compulsive Disorder ◽  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Genetic Models ◽  
Obsessive Compulsive ◽  
Val66met Polymorphism ◽  
Compulsive Disorder ◽  
Bdnf Val66met Polymorphism

ObjectiveBrain-derived neurotrophic factor (BDNF) plays an important role in neural survival and was proposed to be related to psychiatric disorders. Val66Met (also known as rs6265 or G196A), the only known functional polymorphism of the BDNF gene, has been widely studied and considered to be associated with risk of some psychiatric disorders such as bipolar disorder and schizophrenia. However, studies evaluating its association with obsessive–compulsive disorder (OCD) obtained inconsistent results. The purpose of this study was to derive a more precise estimation of the association between BDNF Val66Met polymorphism and OCD susceptibility by a meta-analysis.MethodWe carried a structured literature search in PubMed, Embase, PsycINFO and Chinese Biomedical Database up to December 2014; and retrieved all eligible case–control studies according to the including criteria. Meta-analysis was performed for four genetic models: allelic model: Met versus Val; additive model: Met/Met versus Val/Val; recessive model: Met/Met versus Val/Val+Val/Met; and dominant model: Val/Met+Met/Met versus Val/Val. Stratified analyses were performed by ethnicity and gender where appropriate.ResultsA total of eight articles with nine studies including 1632 OCD cases and 2417 controls were identified. No significant association was detected in any comparison when the whole data were pooled together or stratified by ethnicity or gender in all four genetic models (p>0.05 for each comparison).ConclusionDespite some limitations, our meta-analysis suggests that no significant association exists between the BDNF Val66Met polymorphism and OCD susceptibility.

scholarly journals Symptom Dimensions and Brain-Derived Neurotrophic Factor Val66Met Polymorphism in Obsessive-compulsive Disorder

2020 ◽  
Vol 6 (2) ◽  
pp. 84-93
Author(s):  
Shahrzad Hoveyda ◽  
◽  
Javad Khalatbari ◽  
Javid Peymani ◽  
Hasan Ahadi ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Recessive Model ◽  
Obsessive Compulsive ◽  
Val66met Polymorphism ◽  
Symptom Dimensions ◽  
Compulsive Disorder ◽  
Diagnostic And Statistical Manual ◽  
Bdnf Val66met Polymorphism

Background: Obsessive-Compulsive Disorder (OCD) is a serious neuropsychiatric disorder. The clinical prominence of the OCD symptoms dimensions and Brain-Derived Neurotrophic Factor (BDNF) Val66Met polymorphism are of significant importance. Objectives: The present study aimed to investigate the symptom dimensions and BDNF val66Met polymorphism genotype in Iranian patients with OCD. Materials and Methods: A total of 83 patients diagnosed with OCD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM5) criteria, and 83 matched controls were included this case-control study. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was used to investigate symptom dimensions. In addition, BDNF val66Met polymorphism was genotyped using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCRRFLP) method. Results: The obtained data indicated that the most prevalent obsession was contamination (62.6%) and the most prevalent compulsion was cleanliness (69.8%). Furthermore, there was a significant relationship between the genotypes of BDNF val66Met polymorphism in OCD (P<0.01). Besides, carrying the” T” allele confers increased the risk for the presence of OCD [χ2=4.7, P=0.003; OR (95%) 1.93 (1.24-2.99)]. Conclusion: The symptoms dimensions of OCD in the Iranian sample were similar to other populations. Moreover, the findings suggested an association between BDNF val66Met polymorphism genotype and OCD in the explored Iranian sample. The inheritance hypothesis for the TT genotype was the recessive model.

Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive–compulsive disorder

CNS Spectrums ◽  
2021 ◽  
pp. 1-7
Author(s):  
Ghina Harika-Germaneau ◽  
Nicolas Langbour ◽  
Sylvie Patri ◽  
Marcello Solinas ◽  
Armand Chatard ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Response To Treatment ◽  
Obsessive Compulsive ◽  
Val66met Polymorphism ◽  
Symptom Dimensions ◽  
Compulsive Disorder ◽  
Symptom Dimension ◽  
The Impact

Abstract Objective Obsessive–compulsive disorder (OCD) is a severe psychiatric disorder characterized by its heterogeneous nature and by different dimensions of obsessive–compulsive (OC) symptoms. Serotonin reuptake inhibitors (SRIs) are used to treat OCD, but up to 40% to 60% of patients do not show a significant improvement with these medications. In this study, we aimed to test the impact of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on the efficacy of antidepressants in OCD overall, and in relation to the different OC dimensions. Methods In a 6-month prospective treatment study, 69 Caucasian OCD patients were treated with escitalopram for 24 weeks or with escitalopram for 12 weeks followed by paroxetine for an additional 12-week period. Patients were genotyped and assessed for treatment response. The main clinical outcomes were improvement of the Yale-Brown Obsessive–Compulsive Scale score and in different OC symptom dimension scores. Results The Val/Val group comprised 43 (62%) patients, the Val/Met and Met/Met group comprised 26 (38%) patients. Forty-two patients were classified as responders at 12 weeks and 38 at 24 weeks; no significant association was found between BDNF Val66Met and SRIs response at 12 and 24 weeks. In analyses of the different OC symptom dimensions, the Met allele was associated with a slightly reduced score in the aggressive/checking dimension at 6 months (P = .048). Conclusions Our findings do not support the usefulness of BDNF Val66Met genotyping to predict overall response to treatment with SRIs in OCD; they did however suggest a better outcome at 6 months for the aggressive/checking symptom dimension for patients carrying the Met allele.

Brain-derived neurotrophic factor: A genetic risk factor for obsessive-compulsive disorder and Tourette syndrome?

2006 ◽  
Vol 21 (6) ◽  
pp. 881-883 ◽  
Author(s):  
Stefanie Klaffke ◽  
Inke R. König ◽  
Fritz Poustka ◽  
Andreas Ziegler ◽  
Johannes Hebebrand ◽  
...  
Keyword(s):  
Risk Factor ◽  
Obsessive Compulsive Disorder ◽  
Tourette Syndrome ◽  
Neurotrophic Factor ◽  
Genetic Risk ◽  
Brain Derived Neurotrophic Factor ◽  
Genetic Risk Factor ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

Cortisol and Brain-Derived Neurotrophic Factor Levels Prior to Treatment in Children With Obsessive-Compulsive Disorder

2016 ◽  
Vol 77 (07) ◽  
pp. e855-e859 ◽  
Author(s):  
Şeref Şimşek ◽  
Salih Gençoğlan ◽  
Tuğba Yüksel ◽  
İbrahim Kaplan ◽  
Rümeysa Alaca
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

scholarly journals Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Li He ◽  
Yanhui Liao ◽  
Qiuxia Wu ◽  
Tieqiao Liu
Keyword(s):  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Current Data ◽  
Cochrane Library ◽  
Case Control Studies ◽  
Val66met Polymorphism ◽  
Asian Populations ◽  
Bdnf Val66met Polymorphism ◽  
Relationship Of

Background: Several studies had examined the association between brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and methamphetamine (METH) use disorder, whereas the results were conflicting. The aim of this study was to conduct a meta-analysis to achieve a pooled effect size of the association between BDNF Val66Met polymorphism and METH use disorder.Methods: Literature searches were conducted in PubMed, EMBASE, and Cochrane Library up to July, 2020. All relevant studies on the relationship of BDNF Val66Met polymorphism and METH addiction were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated in the dominant, recessive, co-dominant, and allele model to appraise the association.Results: Seven case–control studies with a total of 2,204 subjects (956 METH-dependent cases and 1,248 healthy controls) were included in this meta-analysis. The results showed a significant correlation between BDNF Val66Met polymorphism and METH dependence in overall population under different genetic models. However, subgroup analysis indicated that the association only existed in Han Chinese but not in other Asian populations.Conclusion: Although the current data indicate that BDNF Val66Met polymorphism might be a potential genetic factor for METH use disorder, more researches are needed to prove its role in different populations.

Sign in / Sign up

Export Citation Format

Share Document